tbuckley/cabot-search huggingface dataset:
#Cardioonc
Authors: Samuel B. Jackson, Michael Tanoue, Negeen Shahandeh, Juan Lopez-Mattei, Sherry-Ann Brown, Janet K. Han, Eric H. Yang
Journal: JACC CardioOncology (2021)

witter is a social media and microblogging ser- vice that has grown in popularity since its inception, both in the public domain and more recently within many academic spheres (1,2).Twitter use during major cardiovascular symposia has recently gained significant traction because of its ability to deliver relevant scientific data in real-time to a global audience (3-5).Although prior work has illustrated an increase in Twitter use during cardiovascular meetings (1), data regarding its application within the field of cardio-oncology are lacking.Although data also suggest that social media facilitates medical education (5), our viewpoint is that there is an important need to better understand the impact and the quality of the information shared on Twitter (1-4).To inform our viewpoint, we analyzed Twitter use within the field of cardio-oncology through a detailed assessment of utilization trends during 5 major cardiovascular and 5 major oncological meetings from 2014 to 2018.We evaluated the utility of social media as a tool for medical education through content analysis of tweets for scientific relevance and educational value.Symplur Signals (Symplur LLC, Los Angeles, California), a health care social media analytics platform, was used to access data for the 2 official hashtags within cardio-oncology: #CardioOnc and #CardioOncology.Hashtags used during 5 major cardiology and 5 major oncology conferences from 2014 to 2018 were analyzed (Figure 1).Official dates of these conferences were listed on the respective society websites.The analysis period for each session was defined as 3 days before the official beginning of the conference, the conference itself, and 3 days following the conclusion of the conference.Institutional review board review was not required per the primary authors' institutional policy, because Symplur's database draws on publicly available data.All tweets published during the study period were analyzed for relevance and content by a single independent physician reviewer (S.B.J.); ambiguity was resolved by a second reviewer (E.H.Y
Megakaryocytes Mediate Hyperglycemia-Induced Tumor Metastasis
Authors: Biying Wu, Ying Ye, Sisi Xie, Yintao Li, Xiaoting Sun, Mengyuan Lv, Ling Yang, Nan Cui, Qiying Chen, Lasse D. Jensen, Dongmei Cui, Guichun Huang, Ji Zuo, Shaochong Zhang, Wen Liu, Yunlong Yang
Journal: Cancer Research (2021)

High blood glucose has long been established as a risk factor for tumor metastasis, yet the molecular mechanisms underlying this association have not been elucidated. Here we describe that hyperglycemia promotes tumor metastasis via increased platelet activity. Administration of glucose, but not fructose, reprogrammed the metabolism of megakaryocytes to indirectly prime platelets into a prometastatic phenotype with increased adherence to tumor cells. In megakaryocytes, a glucose metabolism-related gene array identified the mitochondrial molecular chaperone glucose-regulated protein 75 (GRP75) as a trigger for platelet activation and aggregation by stimulating the Ca2+-PKCα pathway. Genetic depletion of Glut1 in megakaryocytes blocked MYC-induced GRP75 expression. Pharmacologic blockade of platelet GRP75 compromised tumor-induced platelet activation and reduced metastasis. Moreover, in a pilot clinical study, drinking a 5% glucose solution elevated platelet GRP75 expression and activated platelets in healthy volunteers. Platelets from these volunteers promoted tumor metastasis in a platelet-adoptive transfer mouse model. Together, under hyperglycemic conditions, MYC-induced upregulation of GRP75 in megakaryocytes increases platelet activation via the Ca2+-PKCα pathway to promote cancer metastasis, providing a potential new therapeutic target for preventing metastasis. SIGNIFICANCE: This study provides mechanistic insights into a glucose-megakaryocyte-platelet axis that promotes metastasis and proposes an antimetastatic therapeutic approach by targeting the mitochondrial protein GRP75.
Firearm Injuries’ Impact on US Children
Authors: Megan L. Ranney
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Examining patient specific factors associated with inpatient hospital length of stay for solid tumor oncology patients from low socioeconomic communities in Milwaukee, WI.
Authors: Sailaja Kamaraju, Bethany Canales, Tamiah Wright, John A. Charlson, Aniko Szabo, Donggwan Lee, Thomas Wetzel, Kevin Richardson, Kathleen Jensik, Steve Power, Grace Campbell
Journal: Journal of Clinical Oncology (2021)

232 Background: In a retrospective analysis at the Medical College of Wisconsin’s Cancer Center, we identified longer inpatient length of stay (LOS) for patients residing in low-socioeconomic (SES) ZIP Codes in Milwaukee County compared to their high-SES counterparts in 2020 (7.3 days compared to 7.1 days). Under the auspices of American Society of Clinical Oncology’ Quality Training Program (QTP) initiative, this study examined specific factors related to prolonged LOS for solid tumor oncology patients. Methods: This analysis includes initial CY20 LOS medical record data for select patient service areas. Supplemental data includes disease registry data, diagnostic data, and SES data determined by patient ZIP Code. We identified patients 18 years and older with a diagnosis of common oncologic malignancies from 1/1/2020-12/31/2020 (breast, gastrointestinal (GI), genitourinary (GU), gynecologic (GYN), head and neck (H&amp;N), and lung cancers). Poisson regression models with robust standard errors were used to compare the LOS index (LOSi) between groups of patients based on race, SES group, primary payer, and BMI. Results: A total of 1,637 patients with solid tumor diagnosis admitted to hematology and oncology units were identified. The LOSi did not vary significantly by race (range 0.95 – 1.07, p = 0.40) or primary payer (range 0.99 – 1.04, p = 0.59), but lower SES groups tended to have longer LOSi, with LOSi ratio above 1 compared to high SES (low SES: 1.16, p = 0.2; medium-low SES: 1.24, p = 0.06). Among patients with breast cancer diagnosis, Black (LOSi = 1.24, p = 0.01), medium-low SES (LOSi = 1.46, p = 0.02), Medicaid (LOSi = 1.40, p = 0.00), underweight (LOSi = 1.66, p = 0.00), and overweight (LOSi = 1.23, p = 0.01) patients had slightly longer LOSi, with LOSi ratio above 1. Among patients with H&amp;N cancer diagnosis, Black patients (LOSi = 0.77, p = 0.02) had slightly shorter LOSi, with LOSi ratio below 1. The LOSi did not vary significantly by other factors for patients with H&amp;N cancer diagnosis or the other common oncologic malignancies evaluated. Conclusions: This study shows how patient-specific factors such as race, SES, primary payer, and BMI contribute to inpatient LOS. Healthcare systems may benefit by addressing patient-specific barriers and factors such as body mass index, SES and SDH, to reduce hospital LOS.
ST-Segment Elevation Myocardial Infarction Mimic
Authors: Chuan-Hai Zhang, Ting-Ting Li
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Authors: Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic Moore, Karen P. McKinnon, Alec D. Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan A. Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo
Journal: Blood Cancer Discovery (2021)

Abstract Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-1 inhibition improves clinical responses in relapsed/refractory (R/R) AML. Overall responders could receive pembrolizumab maintenance up to 2 years. Among 37 patients enrolled, the overall response rate, composite complete remission (CRc) rate (primary endpoint), and median overall survival (OS) were 46%, 38%, and 11.1 months, respectively. Patients with refractory/early relapse and those receiving treatment as first salvage had encouraging outcomes (median OS, 13.2 and 11.3 months, respectively). Grade ≥3 immune-related adverse events were rare (14%) and self-limiting. Patients who achieved CRc had a higher frequency of progenitor exhausted CD8+ T cells expressing TCF-1 in the bone marrow prior to treatment. A multifaceted correlative approach of genomic, transcriptomic, and immunophenotypic profiling offers insights on molecular correlates of response and resistance to pembrolizumab. Significance: Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage regimen. Further study of pembrolizumab and other immune-checkpoint blockade strategies after cytotoxic chemotherapy is warranted in AML. See related commentary by Wei et al., p. 551. This article is highlighted in the In This Issue feature, p. 549
Implications of immunomodulatory medications in covid-19 infected hematological malignancy patients in Qatar
Authors: A. A. Battah, M. Aldapt, A. Ahmad, M. Osman, H. Elsabah, K. A. Aboudi, H. E. Omri, R. Taha
Journal: HemaSphere (2021)

Background: Immunomodulatory medications including monoclonal antibodies are widely used in the treatment of many hematological malignancies, however their use during the COVID-10 pandemic was associated with worse outcome for some patients. Aims: To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels Methods: To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels Results: during the study period we reviewed 50 patients with hematological malignancy who were diagnosed with confirmed COVID-19 since March 2020, 8 patients fit the inclusion criteria, all of them were having advanced stage lymphoma at some point. 4 patients died, 75% of them had ECOG ≥2 & all of them never cleared the COVID-19 virus, 3 patients recovered, 1 is still recovering but still has reactive COVID PCR test, remains in very stable condition. the other 4 patents who recovered, 2 cleared their infection within 14 days, 1 patient had reinfection within 3 months & 1 still has positive COVID PCR after 30 days of infection, all of them were in complete remission at time of COVID-19 infection & all of them has mild infection Summary/Conclusion: Treatment with monoclonal antibodies including regimens during COVID-19 pandemic should be used with caution in regards of its outstanding benefits vs risk of severe & fatal COVID-19 infection in this critical point of time. It was noticed that achieving hematologocal remission is an important factor in patient survival & recovery from COVID-19 infection, patient who died had lower COVID-19 PCR CT values than the patients who survived & never cleared the virus, however survivors mostly had delayed viral clearance than general population in general.
Effect of rivaroxaban (10mg) versus observation on the risk of thrombosis at discharge in individuals with covid-19
Authors: C. Ramos, E. Madera, A. Majlufc, A. Cabrera, D. MacEdo, U. Valencia, C. Balderas, E. Camargo, M. Bejarano, C. Martinez, E. Rosas
Journal: HemaSphere (2021)

Background: Coagulopathy associated with COVID-19 is one of the main complications, especially in individuals with risk factors. Simultaneously, the use of low molecular weight heparin is the recommended strategy in hospitalized individuals, but the usefulness of other strategies such as DOACs in outpatients is still unknown. Aims: Describe the benefit of the use of rivaroxaban at discharge on the risk of thrombosis in patients discharged from COVID-19.Identify the behavior of Dimero-D at discharge and its modification with anticoagulant therapy. Methods: Randomized 1: 1 study (Rivaroxaban 10mg for 14 days versus observation) at discharge in individuals with COVID-19 who have not required mechanical ventilation. D-dimer was evaluated at 14 and 30 days after discharge in conjunction with a CT angiography at four weeks after hospital discharge. The protocol was developed in the Hospital Regional de Alta Especialidad de Ixtapaluca, authorized by the ethics committee with registration number NR-19-2020. The study is identified in ClinicalTrials.gov with the following registry NCT04508439 Results: Forty individuals were evaluated (20 in each arm) with follow- up greater than 100 days. Gender distribution was equitable in each arm, with a mean age of 50 years (21 to 74 years), 40% (n = 16) were older than 55 years, 27.5% (n = 11) had hypertension and 20% (n = 8) had diabetes. The mean length of hospital stay was 10.5 days (6 to 23 days) treated with oxygen and low molecular weight heparin. At discharge, treatment was started with rivaroxaban 10mg x 14d vs. observation;in the rivaroxaban group, four events were identified (3 hemorrhages / 1 thrombosis), this difference being significant (Log Rank 0.016). Only one thrombosis event (pulmonary embolism) was identified in the rivaroxaban group at eight treatment days. Compared to the diagnosis, DD levels were lower at both 14 and 30 days (p = 0.000, 95% CI, 440.8-1164.9) without finding a difference in those treated with rivaroxaban or observation (p = 0.721, 95% CI, -68.48 to 241.18). Summary/Conclusion: The use of DOACs at discharge does not benefit from an increased risk of hemorrhagic events;the anticoagulant strategy should be individualized, focused only on those patients at very high risk of thrombosis.
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer
Authors: Yi Ban, Geoffrey J. Markowitz, Yue Zou, Divya Ramchandani, Jeffrey Kraynak, Jianting Sheng, Sharrell B. Lee, Stephen T. C. Wong, Nasser K. Altorki, Dingcheng Gao, Vivek Mittal
Journal: Nature Cancer (2021)
P08.01 Immune-Related Acute Motor Axonal Neuropathy: A Small Case Series and Review of the Literature
Authors: Y Pina, N Tran, P Forsyth, S Mokhtari, E Peguero
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Immunotherapy have revolutionized cancer treatment in the past decade, with a significant increased survival in patients with solid tumors. However, the use of immune checkpoint inhibitors (ICIs) has been associated with a growing number of neurotoxicities, some of which can be fatal if not recognized and treated promptly. Some of these neurotoxicities include very uncommon syndromes like Acute Motor Axonal Neuropathy (AMAN). Herein we present four oncological cases of patients who underwent immunotherapy and developed AMAN. METHODS Four patients were diagnosed with immune-related AMAN between 2017 and 2000 at H. Lee Moffitt Cancer Center. The patients were treated with standard of care and currently follow up in clinic. RESULTS We describe four oncological patients who developed a motor axonal neuropathy (i.e., AMAN) confirmed on nerve conduction studies following 2 cycles of immunotherapy, including a 28 year old woman with melanoma brain metastasis and a 50 year old woman with renal cell carcinoma both treated with ipilimumab and nivolumab, a 32 year old man with Hodgkin lymphoma who was treated with nivolumab and brentuximab, and a 77 year old woman with renal urothelial cancer who was treated with pembrolizumab and cabozantinib. All four patients were promptly recognized as having immune-related neurotoxicity (irNs), were promptly treated (i.e., high dose steroids +/- IVIG +/- other immunomodulators), and significantly improved and have remained stable. CONCLUSION This is the first case series of patients with AMAN following two cycles of immunotherapy, who were successfully treated. It is crucial to develop a better understanding of the irNs associated with ICIs, including those rare conditions that are difficult to diagnose and treat, as the utilization of these immunomodulating therapies continues to increase and expand to include other solid malignancies. Neurologists should be involved early on in any case of suspected irN to assist in the management of these complicated patients and a swift work up should be initiated for timely diagnosis and treatment.
Combined treatment of CHC with isoprinosine and IFNa: Th1/Th2 cytokines and responsiveness to therapy.
Authors: NA Osna, EY Hagina, N Vilgert, GI Silonova, AM Sochnev, R Latvia, A Zvirbliene, M Mauricas, V Kuse, A Ambrozaitis, SW Schalm
Journal: Hepatology (1999)
Perioperative Management of Do-Not-Resuscitate Orders at a Large Academic Health System
Authors: Rachel A. Hadler, Mia Fatuzzo, Gurmukh Sahota, Mark D. Neuman
Journal: JAMA Surgery (2021)

Perioperative Management of Do-Not-Resuscitate Orders at a Large Academic Health SystemIndividuals with do-not-resuscitate (DNR) orders may undergo surgery for symptom relief or to treat reversible conditions.Resuscitative procedures, such as intubation, are frequently necessary to deliver anesthesia and sedation safely.Guidelines recommend that each patient's DNR order be reevaluated preoperatively to ascertain the need for modification or temporary suspension. 1,2 Available evidence suggests incomplete implementation of such guidance. [3]4][5][6] We per-formed a retrospective analysis of orders and documentation describing perioperative management of patients' DNR orders at 1 academic health system in the US.
Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019
Authors: Lorenzo Subissi, Nathalie Bossuyt, Marijke Reynders, Michèle Gérard, Nicolas Dauby, Patrick Lacor, Siel Daelemans, Bénédicte Lissoir, Xavier Holemans, Koen Magerman, Door Jouck, Marc Bourgeois, Bénédicte Delaere, Sophie Quoilin, Steven Van Gucht, Isabelle Thomas, Cyril Barbezange
Journal: Eurosurveillance (2021)

BackgroundSeasonal influenza-like illness (ILI) affects millions of people yearly. Severe acute respiratory infections (SARI), mainly influenza, are a leading cause of hospitalisation and mortality. Increasing evidence indicates that non-influenza respiratory viruses (NIRV) also contribute to the burden of SARI. In Belgium, SARI surveillance by a network of sentinel hospitals has been ongoing since 2011.AimWe report the results of using in-house multiplex qPCR for the detection of a flexible panel of viruses in respiratory ILI and SARI samples and the estimated incidence rates of SARI associated with each virus.MethodsWe defined ILI as an illness with onset of fever and cough or dyspnoea. SARI was defined as an illness requiring hospitalisation with onset of fever and cough or dyspnoea within the previous 10 days. Samples were collected in four winter seasons and tested by multiplex qPCR for influenza virus and NIRV. Using catchment population estimates, we calculated incidence rates of SARI associated with each virus.ResultsOne third of the SARI cases were positive for NIRV, reaching 49.4% among children younger than 15 years. In children younger than 5 years, incidence rates of NIRV-associated SARI were twice that of influenza (103.5 vs 57.6/100,000 person-months); co-infections with several NIRV, respiratory syncytial viruses, human metapneumoviruses and picornaviruses contributed most (33.1, 13.6, 15.8 and 18.2/100,000 person-months, respectively).ConclusionEarly testing for NIRV could be beneficial to clinical management of SARI patients, especially in children younger than 5 years, for whom the burden of NIRV-associated disease exceeds that of influenza.
Keynote Session: Strategies for Prevention and Control of HPV-Associated Cancers
Authors: Lillian R. Kreppel, Shivan J. Mehta, Mark H. Sawyer, Edward L. Trimble, Susan T. Vadaparampil, moderated by Wui-Jin Koh
Journal: Journal of the National Comprehensive Cancer Network (2021)

Infection with HPV is responsible for 5% of cancers, most of which are preventable with vaccination. Unfortunately, although vaccination rates are increasing in the United States, many adolescents remain unvaccinated due to a multifactorial set of barriers that are cultural, psychosocial, structural, and financial. At this Keynote session at the NCCN 2021 Virtual Annual Conference, a selection of expert panelists discussed efforts to improve vaccination rates.